Neuroscience for Addiction Medicine: From Prevention to Rehabilitation - Methods and Interventions

Part I: Neuroscience Methods for Addiction Medicine

• Chapter 1: Animal models for addiction medicine: From vulnerable phenotypes to addicted individuals
  • Abstract
  • 1 Introduction
  • 2 Types of Animal Models
  • 3 Conclusions and Future Directions
  • Acknowledgments
• Chapter 2: Animal models of drug relapse and craving: From drug priming-induced reinstatement to incubation of craving after voluntary abstinence
  • Abstract
  • 1 Introduction
  • 2 Extinction-based Relapse Models
  • 3 Abstinence-Based Relapse Models
  • 4 Conclusions
  • Acknowledgments
• Chapter 3: Computational modeling for addiction medicine: From cognitive models to clinical applications
  • Abstract
  • 1 IGT and SGT decision-making Tasks
  • 2 The EVL and PVL Models
  • 3 Applications of the EVL and PVL Models to Clinical Populations Including Addiction
  • 4 Conclusion and Future Directions
  • Acknowledgments
• Chapter 4: Electrophysiology for addiction medicine: From methodology to conceptualization of reward deficits
  • Abstract
  • 1 Gearing Up: Employing Electrophysiology to Study Reward in Addiction
  • 2 What Terrain Have We Covered in the Past Decade?
  • 3 Roadmap for Our Journey
  • 4 Our Tools: Electrophysiological Markers of Reward
  • 5 Comparing and Contrasting Types of Addiction
  • 6 Promising Avenues Ahead
• Chapter 5: Neurocognitive rehabilitation for addiction medicine: From neurophysiological markers to cognitive rehabilitation and relapse prevention
  • Abstract
  • 1 Introduction
  • 2 A Possible Role for ERPs
  • 3 Preliminary Evidence from Alcohol Abuse Studies
  • 4 Converging Evidence from Other Addictive States
  • 5 Conclusion and Future Directions
  • Acknowledgments
• Chapter 6: Structural imaging for addiction medicine: From neurostructure to neuroplasticity
  • Abstract
  • 1 Introduction
  • 2 Marijuana
  • 3 Adolescence (average Sample Age ≤ 21)
  • 4 Adulthood (average Sample Age ≥ 22, on Average)
  • 5 Stimulants
  • 6 Prenatal Exposure
  • 7 Exposure in Adolescence and Adulthood
  • 8 Opiates
  • 9 Quantitative Morphometry
  • 10 Diffusion Tensor Imaging
  • 11 Treatment Implications
  • 12 Conclusions and Future Directions
• Chapter 7: Functional neuroimaging for addiction medicine: From mechanisms to practical considerations
  • Abstract
  • 1 Introduction
  • 2 Main Cognitive Targets in fMRI for Addiction Medicine
  • 3 Resting-State fMRI for Addiction Medicine
  • 4 fMRI Studies in Addiction Populations
  • 5 Possible Applications of fMRI for Addiction Medicine
  • 6 Major Challenges to fMRI for Addiction Medicine
  • 7 Conclusion and Future Directions
  • Acknowledgments
• Chapter 8: Resting state functional connectivity analysis for addiction medicine: From individual loci to complex networks
  • Abstract
  • 1 Introduction
  • 2 Conclusions and Future Directions
  • Acknowledgments
• Chapter 9: PET imaging for addiction medicine: From neural mechanisms to clinical considerations
  • Abstract
  • 1 Introduction
  • 2 PET Technologies to Study the Neurobiological Mechanisms Underlying Addiction
  • 3 PET Studies on Dopaminergic Neurotransmission in Addiction
  • 4 PET Studies in Addiction Beyond DA
  • 5 Future Directions
  • 6 PET, a Diagnostic Instrument?
  • 7 Conclusion and Future Directions
  • Acknowledgments
• Chapter 10: Genetic imaging consortium for addiction medicine: From neuroimaging to genes
  • Abstract
  • 1 Introduction
  • 2 Genetic Basis of Addiction
  • 3 Enhancing Neuroimaging Genetics Through Meta-analysis
  • 4 ENIGMA Addiction Working Group
  • 5 Summary and Future Directions
  • Acknowledgments

Part II: Neuroscience for Interventions in Addiction Medicine

• Chapter 11: Human pharmacology for addiction medicine: From evidence to clinical recommendations
  • Abstract
  • 1 Introduction
  • 2 Alcohol Use Disorders
  • 3 Nicotine
  • 4 Opioid Use Disorders
  • 5 Cocaine and Amphetamines
  • 6 Cannabis
  • 7 Benzodiazepines
  • 8 Gamma-Hydroxybutyrate
  • 9 Conclusion and Future Directions
  • Acknowledgments
• Chapter 12: Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics
  • Abstract
  • 1 Introduction
  • 2 Peroxisome Proliferating Activator Receptors
  • 3 cAMP Response Element-binding Protein and the Inhibition of Phosphodiesterase Enzymes
  • 4 Stress-related Neuropeptides
  • 5 Conclusion and Future Directions
  • Acknowledgments
• Chapter 13: Cognitive interventions for addiction medicine: Understanding the underlying neurobiological mechanisms
  • Abstract
  • 1 Introduction
  • 2 Cognitive Interventions
  • 3 Summary
  • 4 Conclusion and Future Directions
  • Acknowledgments
• Chapter 14: Adolescent psychotherapy for addiction medicine: From brain development to neurocognitive treatment mechanisms
  • Abstract
  • 1 Overview
  • 2 Adolescent Brain Development and Addiction
  • 3 Neurocognitive Responses to Intervention
  • 4 Conclusions and Future Directions
• Chapter 15: Cognitive neuroscience of cognitive retraining for addiction medicine: From mediating mechanisms to questions of efficacy
  • Abstract
  • 1 Introduction
  • 2 Cognitive Bias Modification
  • 3 Mechanisms of CBM
  • 4 CBM: (When) Does It Work?
  • 5 Developments in dual-process Models
  • 6 Enhancing Efficacy and Efficiency of CBM
  • 7 Conclusion and Future Directions
• Chapter 16: Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders: From cognitive improvement to relapse prevention
  • Abstract
  • 1 Introduction
  • 2 Potential Cognitive Targets for Rehabilitation
  • 3 Cognitive Rehabilitation Therapy Methods
  • 4 Efficacy of Neurocognitive Rehabilitation in Addiction Medicine
  • 5 Methods for Presenting the Rationale of CRT to Patients with Addictions
  • 6 Principles of Cognitive Rehabilitation for Drug Addiction
  • 7 Challenges of CRT for Addiction
  • 8 Conclusions and Future Directions
  • Acknowledgments
• Chapter 17: Noninvasive brain stimulation for addiction medicine: From monitoring to modulation
  • Abstract
  • 1 Introduction
  • 2 NIBS for Neurochemical and Neuroplasticity Assessments
  • 3 Using Repetitive NIBS as a Mechanistic and Therapeutic Tool
  • 4 NIBS and Clinical Practice in Addiction Medicine: Limitations, Open Problems, and Future Directions
  • Acknowledgments
• Chapter 18: What the alcohol doctor ordered from the neuroscientist: Theragnostic biomarkers for personalized treatments
  • Abstract
  • 1 Introduction
  • 2 Individual Treatment Predictive Biomarkers: Theragnostics
  • 3 Alcohol-induced Dopamine Activation as a Theragnostic Biomarker
  • 4 Measures of Glutamate Activity as Theragnostic Biomarkers
  • 5 Conclusions and Future Directions
• Chapter 19: What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses
• Abstract
• 1 Introduction
• 2 Part 1: Understanding the NeuroCircuitry of Addiction and Use the Power of Brain Stimulation
• 3 Part 2: Understanding the Neurochemical Signature of Addiction and Use this to Impact Clinical Care
• 4 Part 3: Understanding the Role of Genetic Factors and Use this to Impact Clinical Care
• 5 Conclusion and Future Directions
• Acknowledgment